Logo Logo
Switch Language to German

Jamal Jameel, Kaschin; Gallert, Willem-Jakob; Yanik, Sarah D.; Panek, Susanne; Kronsbein, Juliane; Jungck, David; Koch, Andrea and Knobloch, Jürgen (2021): Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD. In: International Journal of Molecular Sciences, Vol. 22, No. 13, 7187

Full text not available from 'Open Access LMU'.


In smoking-induced chronic obstructive pulmonary disease (COPD), various comorbidities are linked to systemic inflammation and infection-induced exacerbations. The underlying mechanisms are unclear but might provide therapeutic targets. T-cell activity is central in systemic inflammation and for infection-defense mechanisms and might be influenced by comorbidities. Hypothesis: Circulating biomarkers of comorbidities modulate the activity of T-cells of the T-helper type 1 (Th1) and/or T-cytotoxic type 1 (Tc1). T-cells in peripheral blood mononuclear cells (PBMCs) from non-smokers (NS), current smokers without COPD (S), and COPD subjects (total n = 34) were ex vivo activated towards Th1/Tc1 and were then stimulated with biomarkers for metabolic and/or cardiovascular comorbidities (Brain Natriuretic Peptide, BNP;chemokine (C-C motif) ligand 18, CCL18;C-X3-C motif chemokine ligand 1, CX3CL1;interleukin-18, IL-18) or for asthma- and/or cancer-related comorbidities (CCL22;epidermal growth factor, EGF;IL-17;periostin) each at 10 or 50 ng/mL. The Th1/Tc1 activation markers interferon-gamma (IFN gamma), tumor necrosis factor-alpha (TNF alpha), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were analyzed in culture supernatants by Enzyme-Linked Immunosorbent Assay (ELISA). Ex-vivo activation induced IFN gamma and TNF alpha without differences between the groups but GM-CSF more in S vs. NS. At 10 ng/mL, the different biomarkers increased or reduced the T-cell activation markers without a clear trend for one direction in the different categories of comorbidities or for the different T-cell activation markers. At 50 ng/mL, there was a clear shift towards suppressive effects, particularly for the asthma- and cancer-related biomarkers and in cells of S and COPD. Comorbidities might suppress T-cell immunity in COPD. This could explain the association of comorbidities with frequent exacerbations.

Actions (login required)

View Item View Item